EM703: improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 102209284 |
| MeSH ID | M0497495 |
| Synonym |
|---|
| em703 |
| XOBMIYSKMVYGLU-DWHVFYFZSA-N |
EM703 is a new derivative of erythromycin (EM) without the bactericidal effects. Has a potent promoting activity of monocyte-to-macrophage differentiation in vitro.
| Excerpt | Reference | Relevance |
|---|---|---|
| "EM703 is a new derivative of erythromycin (EM) without the bactericidal effects." | ( EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts. Abe, S; Azuma, A; Hirata, Y; Inagaki, H; Kawada, T; Kudoh, S; Li, YJ; Matsuda, K; Omura, S; Shimizu, T; Sunazuka, T; Takahashi, S; Usuki, J, 2006) | 2.5 |
| "EM703, which is an erythromycin derivative synthesized by our group, has a potent promoting activity of monocyte-to-macrophage differentiation in vitro. " | ( Three-dimensional solution structure of EM703 with potent promoting activity of monocyte-to-macrophage differentiation. Gouda, H; Hirono, S; Omura, S; Sakoh, Y; Sugawara, A; Sunazuka, T; Yoshida, K, 2006) | 2.04 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "EM703 did not inhibit COL1A1 transcription when the luciferase assay was performed using DNA containing the COL1A1 promoter with a short substitution mutation of the CCAAT box." | ( EM703, the new derivative of erythromycin, inhibits transcription of type I collagen in normal and scleroderma fibroblasts. Hamasaki, Y; Hatamochi, A; Ikeda, H; Omura, S; Sunazuka, T; Suzuki, H; Yamazaki, S, 2008) | 2.51 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||